Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Ukoniq, New Targeted Therapy, FDA Approved for Marginal-Zone and Follicular Lymphoma

JHOP - April 2021 Vol 11, No 2 - FDA Oncology Update, Lymphoma
Download PDF

On February 5, 2021, the FDA approved umbralisib (Ukoniq; TG Therapeutics), an oral kinase inhibitor, for the treatment of adults with relapsed or refractory marginal-zone lymphoma (MZL) or with relapsed or refractory follicular lymphoma (FL). Umbralisib is indicated for MZL after ≥1 CD20-directed regimens, and for FL after ≥3 lines of systemic therapy.

Umbralisib is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA, which granted it priority review for MZL and an orphan drug designation for MZL and FL.

“MZL and FL remain incurable diseases, with limited treatment options for patients who relapse after previous therapy and no defined standard of care. With the approval of umbralisib we now have a targeted, oral, once daily option, offering a needed treatment alternative for patients,” said Nathan H. Fowler, MD, Professor of Medicine, The University of Texas M.D. Anderson Cancer Center.

This FDA approval of umbralisib was based on 2 single-arm cohorts of the open-label, multicenter UNITY clinical trial that included 69 patients with MZL and 117 patients with FL who have received several lines of previous therapy. In the study, all patients received oral umbralisib 800 mg once daily until disease progression or until unacceptable toxicity. The efficacy outcome measures were overall response rate (ORR) and duration of response (DOR).

The ORR was 49% among the patients with MZL (95% confidence interval [CI], 37-61.6), with 16% reaching a complete response; the median DOR was not reached (95% CI, 9.3-not estimable). In the patients with FL, the ORR was 43% (95% CI, 33.6-52.2) and 3% achieved a complete response; the median DOR was 11.1 months (95% CI, 8.3-16.4).

The most common (≥15%) adverse reactions with umbralisib were increased creatinine, diarrhea/colitis, fatigue, nausea, neutropenia, transaminase elevation, musculoskeletal pain, anemia, thrombocytopenia, upper respiratory tract infection, vomiting, abdominal pain, decreased appetite, and rash.

Serious adverse reactions occurred in 18% of patients, and most often resulted from diarrhea/colitis and infection. Diarrhea/colitis and transaminase elevation were the most common reasons for dose modifications.

Related Items
Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, Platinum-Resistant Ovarian Cancer
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Rezlidhia New IDH1 Inhibitor FDA Approved for Relapsed or Refractory AML with IDH1 Mutation
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Imjudo, a New CTLA-4 Inhibitor FDA Approved in Combination with Imfinzi for Unresectable Hepatocellular Carcinoma
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic Non–Small-Cell Lung Cancer
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Rylaze Received FDA Approval of a New Dosing Regimen
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Adcetris plus Chemotherapy Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Libtayo plus Platinum-Based Chemotherapy Now FDA Approved for NSCLC without Genomic Aberrations
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Copyright © The Lynx Group, LLC. All rights reserved.